Preparation and Characterization of Poly Lactide-co-glycolide Nanoparticles of SN-38

References

1. 1.↵
   1. Kunii R.,
   2. Onishi H.,
   3. Ueki K.,
   4. Koyama K.,
   5. Machida Y.

   Particle characteristics and biodistribution of camptothecin-loaded PLA/(PEG-PPG-PEG) nanoparticles. Drug Delivery 2008, 15 ( 1), 3– 10.

   OpenUrlPubMed
2. 2.↵
   1. Noda K.,
   2. Nishiwaki Y.,
   3. Kawahara M.,
   4. Negoro S.,
   5. Sugiura T.,
   6. Yokoyama A.,
   7. Fukuoka M.,
   8. Mori K.,
   9. Watanabe K.,
   10. Tamura T.,
   11. Yamamoto S.,
   12. Saijo N

   Japan Clinical Oncology Group. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N. Engl. J. Med. 2002, 346 ( 2), 85– 91.

   OpenUrlCrossRefPubMedWeb of Science
3. 3.↵
   1. Negoro S.,
   2. Masuda N.,
   3. Takada Y.

   CPT-11 Lung Cancer Study Group West. Randomised phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer. Br. J. Cancer 2003, 88 ( 3), 335.
4. 4.↵
   1. Bodurka D. C.,
   2. Levenback C.,
   3. Wolf J. K.

   Phase II trial of irinotecan in patients with metastatic epithelial ovarian cancer or peritoneal cancer. J. Clin. Oncol. 2003, 21 ( 2), 291– 297.

   OpenUrlAbstract/FREE Full Text
5. 5.↵
   Physician Desk Reference, Camptosar®, 57th ed. Thomson Healthcare, Montvale, N.J, 2003.
6. 6.↵
   1. Rothenberg M. L.,
   2. Kuhn J. G.,
   3. Burris H. A., 3rd,
   4. Nelson J.,
   5. Eckardt J. R.,
   6. Tristan-Morales M.,
   7. Hilsenbeck S. G.,
   8. Weiss G. R.,
   9. Smith L. S.,
   10. Rodriguez G. I.,
   11. Rock M. K.,
   12. Von Hoff D. D.

   Phase I and pharmacokinetic trial of weekly CPT-11. J. Clin. Oncol. 1993, 11 ( 11), 2194– 2204.

   OpenUrlAbstract/FREE Full Text
7. 7.↵
   1. Slatter J. G.,
   2. Schaff L. J.,
   3. Sams J. P.

   Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [(14)C] CPT-11 in cancer patients. Drug. Metab. Dispos. 2000, 28 ( 4), 423– 433.

   OpenUrlAbstract/FREE Full Text
8. 8.↵
   1. Gupta E.,
   2. Lestingi T. M.,
   3. Mick R.,
   4. Ramirez J.,
   5. Vokes E. E.,
   6. Ratain M. J.

   Metabolic fate of irinotecan in humans: Correlation of glucuronidation with diarrhea. Cancer Res. 1994, 54 ( 14), 3723– 3725.

   OpenUrlAbstract/FREE Full Text
9. 9.↵
   1. Koizumi F.,
   2. Kitagawa M.,
   3. Negishi T.,
   4. Onda T.,
   5. Matsumota S.,
   6. Hamaguchi T.,
   7. Matsumura Y.

   Novel SN-38-incorporating polymeric micelles, NK012, eradicate vascular endothelial growth factor-secreting bulky tumors. Cancer Res. 2006, 66 ( 20), 10048– 10056.

   OpenUrlAbstract/FREE Full Text
10. 10.↵
    1. Chabner B. A.,
    2. Longo D. L.

    1. Takimoto C. H.,
    2. Arbuck S. G.

    Topoisomerase I targeting agents: The camptothecins. In Cancer Chemotherapy and Biotherapy: Principles and Practice; 3rd ed.; Chabner B. A., Longo D. L.Eds.; Lippincott Williams & Wilkins: Philadelphia, PA, 2001; p 579.
11. 11.↵
    1. Zhang J. A.,
    2. Xuan T.,
    3. Ma M.,
    4. Parmer L.,
    5. Ugwu S.,
    6. Ali S.,
    7. Ahmad I.

    Development and characterization of a novel liposome-based formulation of SN-38. Int. J. Pharm. 2004, 270 ( 1–2), 93– 107.

    OpenUrlCrossRefPubMed
12. 12.↵
    1. Lie S.,
    2. Chien P. Y.,
    3. Sheikh S.,
    4. Zhang A.,
    5. Ali S.,
    6. Ahmad I.

    Enhanced therapeutic efficacy of a novel liposome-based formulation of SN-38 against human tumor models in SCID mice. Anticancer Drugs 2004, 15 ( 8), 773– 778.

    OpenUrlCrossRefPubMed
13. 13.↵
    1. Onishi Y.,
    2. Machida Y.

    Antitumor properties of irinotecan-containing nanoparticles prepared using poly (DL-lactic acid) and poly (ethylene glycol)-block-poly(propylene glycol)-block-poly(ethylene glycol). Biol. Pharm. Bull. 2003, 26 ( 1), 116.
14. 14.↵
    1. Esmaeili F.,
    2. Hosseini-Nasr M.,
    3. Rad-Malekshahi M.,
    4. Samadi N.,
    5. Atyabi F.,
    6. Dinarvand R.

    Preparation and antibacterial activity evaluation of rifampicin-loaded poly lactide-co-glycolide nanoparticles. Nanomedicine: Nanotech. Biol. Medicine 2007, 3 ( 2), 161– 167.

    OpenUrl
15. 15.↵
    1. Esmaeili F.,
    2. Ghahremani M. H.,
    3. Ostad S. N.,
    4. Atyabi F.,
    5. Seyedabadi M.,
    6. Malekshahi M. R.,
    7. Amini M.,
    8. Dinarvand R.

    Folate-receptor-targeted delivery of docetaxel nanoparticles prepared by PLGA-PEG-folate conjugate. J. Drug Targeting 2008, 16 ( 5), 415– 423.

    OpenUrl
16. 16.↵
    1. Esmaeili F.,
    2. Ghahremani B.,
    3. Esmaeili B.,
    4. Khoshayand M. R.,
    5. Atyabi F.,
    6. Dinarvand R.

    PLGA nanoparticles of different surface properties: Preparation and evaluation of their body distribution. Int. J. Pharm. 2008, 349 ( 1–2), 249– 255.

    OpenUrlPubMed
17. 17.↵
    1. Lockman R.,
    2. Mumper R. J.,
    3. Khan M. A.,
    4. Allen D. D.

    Nanoparticles technology for drug delivery across the blood-brain barrier. Drug Dev. Ind. Pharm. 2002, 28 ( 1), 1– 13.

    OpenUrlCrossRefPubMedWeb of Science
18. 18.↵
    1. Grief R.,
    2. Domb A.,
    3. Quellec P.,
    4. Blunk T.,
    5. Müller R. H.,
    6. Verbavatz J. M.,
    7. Langer R.

    The controlled intravenous delivery of drugs using PEG-coated sterically stabilized nanospheres. Adv. Drug Del. Rev. 1995, 16 ( 2–3), 215– 233.

    OpenUrlCrossRef
19. 19.↵
    1. Cappel J.,
    2. Kreuter J.

    Effect of nanoparticles on transdermal drug delivery. J. Microencapsul. 1991, 8 ( 3), 369– 374.

    OpenUrlPubMed
20. 20.↵
    1. Arica B.,
    2. Lamprecht A.

    In vitro evaluation of betamethasone-loaded nanoparticles. Drug Del. Ind. Pharm. 2005, 31 ( 1), 19– 24.

    OpenUrl
21. 21.↵
    1. Pal A.

    Preclinical safety, pharmacokinetics and antitumor efficacy profile of liposome-entrapped SN-38 formulation. Anticancer Res. 2005, 25 ( 1A), 331– 341.

    OpenUrlAbstract/FREE Full Text
22. 22.↵
    1. Sumitomo M.,
    2. Koizumi F.,
    3. Asano T.,
    4. Horiguchi A.,
    5. Ito K.,
    6. Kakizoe T.,
    7. Hayakawa M.,
    8. Matsumura Y.

    Novel SN-38-incorporated polymeric micelle, NK012, strongly suppresses renal cancer progression. Cancer Res. 2008, 68 ( 6), 1631– 1635.

    OpenUrlAbstract/FREE Full Text
23. 23.↵
    1. Soppimath K. S.,
    2. Aminabhavi T. M.,
    3. Kulkarni A. R.,
    4. Rudzinski W. E.

    Biodegradable polymeric nanoparticles as drug delivery devices. J. Controlled Release 70 ( 1–2), 1– 20.
24. 24.↵
    1. Mu L.,
    2. Feng S. S.

    A novel controlled release formulation for the anticancer drug paclitaxel (Taxol): PLGA nanoparticles containing vitamin E TPGS. J. Controlled Release 2003, 86 ( 1), 33– 48.

    OpenUrlCrossRefPubMedWeb of Science
25. 25.↵
    1. Dong Y.,
    2. Feng S. S.

    Methoxy poly(ethylene glycol)-poly(lactide) (MPEG-PLA) nanoparticles for controlled delivery of anticancer drugs. Biomaterials 2004, 25 ( 14), 2843– 2849.

    OpenUrlCrossRefPubMed
26. 26.↵
    1. Murakami H.,
    2. Kobayashi M.,
    3. Takeuchi Y.,
    4. Kawashima Y.

    Preparation of poly (DL-lactide-co-glycolide) nanoparticles by modified spontaneous emulsification solvent diffusion method. Int. J. Pharm. 1999, 187 ( 2), 143– 152.

    OpenUrlCrossRefPubMed
27. 27.↵
    1. Niwa T.,
    2. Takeuchi H.,
    3. Hino T.,
    4. Kunou N.,
    5. Kawashima Y.

    In vitro drug release behavior of D, L-lactide/glycolide copolymer (PLGA) nanospheres with nafarelin acetate prepared by a novel spontaneous emulsification solvent diffusion method. J. Pharm. Sci. 1994, 83 ( 5), 727– 732.

    OpenUrlCrossRefPubMedWeb of Science
28. 28.↵
    1. Le Roy Boehm A. L.,
    2. Zerrouk R.,
    3. Fessi H.

    Poly epsilon-caprolactone nanoparticles containing a poorly soluble pesticide: Formulation and stability study. J. Microencapsul. 2000, 17 ( 2), 195– 205.

    OpenUrlPubMed
29. 29.↵
    1. Paul M.,
    2. Laatiris A.,
    3. Fessi H.,
    4. Dufeu B.,
    5. Durand B.,
    6. Deniau M.,
    7. Astier A.

    Pentamidine-loaded poly(D, L-lactide) nanoparticles: Adsorption and drug release. Drug Dev Res. 1998, 43 ( 2), 98– 104.

    OpenUrl
30. 30.↵
    1. Garderton D.,
    2. Jones T.

    1. Holland S. J.,
    2. Tighe B. J.

    Biodegradable Polymers. In Advanced Pharmaceutical Science; Garderton D., Jones T.Eds; Academic Press: New York, 1992; Vol. 6, p 101.

    OpenUrl